OnCusp Therapeutics receives US FDA fast track designation for CUSP06 for treatment of platinum-resistant ovarian cancer: Princeton, New Jersey Saturday, February 15, 2025, 15:00 ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in ...

This contract involves Da An Biotherapeutics supplying antibodies that LigaChem Biosciences will develop into ADC new drugs. The next-generation cancer treatment core technology, ADC, accurately ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2025, subject to the employee’s continued service with Mersana on each such vesting date. The RSU ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market ...

Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...

To stay up to date on Akari’s recent developments on the Webull Corporate Connect Services Platform, current Webull users can follow AKTX from the app on their smartphone or table device. To download ...

Shares in ADC Therapeutics fell sharply after the company said it had suspended a trial of Zynlonta in previously untreated diffuse large B-cell lymphoma (DLBCL) patients following seven patient ...